Updates in Migraine From a 2018 American Headache Meeting
This program will include a discussion of off-label treatments, devices, and investigational agents not approved by the FDA for use in the United States, and the data were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Acute Treatment of Migraine
Use of Acute Rx Treatments Among CaMEO Study Participants
MAST Study of Unmet Needs in Migraine
RDBPC, Phase 3, Trials of Lasmiditan: SAMURAI and SPARTAN
Dizziness in SAMURAI and SPARTAN
Sumatriptan and Lasmiditan Inhibit KCl-Induced CGRP release
Multicenter, RDBPC, Phase 3, Single-Attack Trial of Ubrogepant
Ubrogepant in Adults With Migraine: Results
Phase 3, RDBPC, Trial of Rimegepant in Adults With Migraine: Study Design
Rimegepant in Adults With Migraine: Results
Sumatriptan vs Rimegepant vs BHV-3500
Prevention of Migraine
Prevention of Migraine: FDA Status of mAbs
RDBPC 12-Week Trial of Fremanezumab for Preventative Treatment of EM: Onset of Efficacy
Rapid Onset of Galcanezumab for the Prevention of EM: EVOLVE-1 and EVOLVE-2
Onset of Efficacy in Phase 3 PROMISE-2 CM Trial
Reversion of CM to EM With CGRP-Targeted mAbs
Post-hoc Analysis of RDBPC Phase 3 Trial of Erenumab in CM: Conversion to EM
Post-hoc Analysis of RDBPC Phase 3 Trial of Fremanezumab in CM: Reversion of EM
The Prevention of Migraine With CGRP-Targeted mAbs: Long-Term Results
Long-Term Data With Erenumab in CM
Treatment of EM and CM Response Over Time With Fremanezumab
The Efficacy of CGRP-Targeted mAbs in Previous Treatment Failure
Galcanezumab After Treatment Failure to OnabotulinumtoxinA in Patients With Migraine
EVOLVE-1, EVOLVE-2, and REGAIN: Galcanezumab in Patients Who Failed to Respond to Preventive Treatments
EVOLVE-1, EVOLVE-2, and REGAIN: Galcanezumab in Patients Who Failed to Respond to Preventive Treatments (cont)
EVOLVE-1, EVOLVE-2, and REGAIN: Galcanezumab in Patients Who Failed to Respond to Preventive Treatments (cont)
Multicenter RDBPC Phase 3a Liberty Trial of Erenumab: Response in Patients With Preventive Treatment Failures
Wolff Award Lecture
Endotypes of Migraine Derived From CaMEO Data
Abbreviations
Abbreviations (cont)